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Abstract Clinicians can use biomarkers to guide thera-
peutic decisions in estrogen receptor positive (ER?) breast
cancer. One such biomarker is cellular proliferation as
evaluated by Ki-67. This biomarker has been extensively
studied and is easily assayed by histopathologists but it is
not currently accepted as a standard. This review focuses
on its prognostic and predictive value, and on methodo-
logical considerations for its measurement and the cut-
points used for treatment decision. Data describing study
design, patients’ characteristics, methods used and results
were extracted from papers published between January
1990 and July 2010. In addition, the studies were assessed
using the REMARK tool. Ki-67 is an independent prog-
nostic factor for disease-free survival (HR 1.05–1.72) in
multivariate analyses studies using samples from random-
ized clinical trials with secondary central analysis of the
biomarker. The level of evidence (LOE) was judged to be
I-B with the recently revised deﬁnition of Simon. However,
E. Luporsi (&)
INSERM, Centre d’Investigations Cliniques-9501, CHU Nancy
& Nancy-Universite ´, 54511 Vandoeuvre-les-Nancy, France
e-mail: e.luporsi@nancy.unicancer.fr
F. Andre ´  M. Spielmann
Department of Oncology, Institut Gustave Roussy, Villejuif,
France
F. Spyratos
Laboratory of Oncogenetics, Institut Curie—Ho ˆpital Rene ´
Huguenin, St-Cloud, France
P.-M. Martin
Translational Laboratory—Biological Oncology, AP-HM,
Marseille, France
J. Jacquemier
Department of Bio-Pathology, Institut Paoli-Calmettes,
Marseille, France
F. Penault-Llorca
Department of Pathology, Centre Jean Perrin and EA 4233,
University of Auvergne, Clermont-Ferrand, France
N. Tubiana-Mathieu
Department of Medical Oncology, CHU Dupuytren, Limoges,
France
B. Sigal-Zafrani
Department of Pathology, Institut Curie, Paris, France
L. Arnould
Department of Tumour Biology and Pathology, Centre Georges-
Franc ¸ois Leclerc, Dijon, France
A. Gompel
Unit of Gynaecology, Universite ´ Paris Descartes, INSERM
UMRS 938, Ho ˆtel-Dieu, AP-HP, Paris, France
C. Egele  M.-P. Chenard  J.-P. Bellocq (&)
De ´partement de Pathologie, Ho ˆpital de Hautepierre, Ho ˆpitaux
Universitaires de Strasbourg, 1 Avenue Molie `re, 67098
Strasbourg Cedex, France
e-mail: jean-pierre.bellocq@chru-strasbourg.fr
B. Poulet
Institut de Pathologie de Paris, 49 rue du Ranelagh, 75016 Paris,
France
K. B. Clough
Department of Surgery, L’Institut du Sein/Paris Breast Center,
Paris, France
H. Crouet
Department of Surgical Oncology, Centre Francois Baclesse,
Caen, France
123
Breast Cancer Res Treat (2012) 132:895–915
DOI 10.1007/s10549-011-1837-zstandardization of the techniques and scoring methods are
needed for the integration of this biomarker in everyday
practice. Ki-67 was not found to be predictive for long-
term follow-up after chemotherapy. Nevertheless, high KI-
67 was found to be associated with immediate pathological
complete response in the neoadjuvant setting, with an LOE
of II-B. The REMARK score improved over time (with a
range of 6–13/20 vs. 10–18/20, before and after 2005,
respectively). KI-67 could be considered as a prognostic
biomarker for therapeutic decision. It is assessed with a
simple assay that could be standardized. However, inter-
national guidelines are needed for routine clinical use.
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Introduction
Both adjuvant, and neoadjuvant chemotherapy and hor-
monal treatment have made a major contribution to
improving disease-free survival (DFS) and overall survival
(OS) in breast cancer [38, 50, 83, 103]. When physicians
prescribe, they consider the risk-to-beneﬁt ratio associated
with a given therapy for a speciﬁc patient because the
therapies have high toxicities. To guide therapeutic deci-
sions, physicians use clinical, histopathological variables
and biomarkers as prognostic or predictive tools, these
latter being most effective if linked with targeted therapies
(companion diagnostics), such as estrogen receptor (ER)
and human epidermal growth factor receptor 2 (HER2) [35,
85, 106].
The ﬁrst aim of this systematic review was to evaluate
the level of evidence (LOE) for Ki-67 as a prognostic
factor or predictive factor of response to chemo- and hor-
monotherapy in patients with invasive breast carcinoma,
and deﬁne its weight in the everyday therapeutic decision-
making process, in particular within the ER? tumour group
in order to select women who are most likely to beneﬁt
from chemotherapy. The second aim was focused on
technical and methodological aspects about the measure-
ment of Ki-67, and on the cut-points used for treatment
decision.
We report data from studies using samples from ran-
domized clinical trials (RCTs), cohort studies, case–control
studies, and we also summarize the results of systematic
and narrative reviews. We paid particular attention to the
methodological aspects of the studies. We took into
account the recommendations published in 2008 by the
National Academy of Clinical Biochemistry and elaborated
by an international panel of experts, which agreed with
those proposed by the ASCO guidelines and complement
them, in particular by their analysis of data related to the
quality of the analytical procedures used [51, 101]. In
addition, the Reporting Recommendations for Tumor
Marker Prognostic Studies (REMARK) score was used to
assess the quality of the reporting of the prognostic study
results [71].
Recently it has been claimed that results from com-
mercially available genomic proﬁling tests (i.e. Mamma-
print
TM, Oncotype DX
) can predict which patients
should receive therapy. Several genes coding for prolif-
eration factors, a key biological driver, are targeted in
these genomic proﬁling tests [12, 26, 58, 112, 113].
Moreover, recent tests, e.g. MapQuant Dx
TM genomic
grade and THEROS BCI
 have been developed to assess
tumour grade molecularly since proliferation is a major
component of tumour grade [113]. Nevertheless, it
remains uncertain if these available genomic proﬁling
tests have signiﬁcant added value when compared with
the histopathological assessment of ER, HER2 and Ki-67,
the latter being routinely used as a marker of prolifera-
tion, although not yet as a standard, in breast cancer
[25, 113].
Ki-67 protein is detected during all the active phases of
the cell cycle, but is absent in resting cells [65]. Since its
discovery in the early 1980s, there has been interest in the
role of Ki-67 as a proliferation marker in cancer,
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123particularly lymphomas, breast, endocrine and brain can-
cers. It is commonly used as a complement to grading
systems that include mitotic counting as a sign of prolif-
eration. Initially, immunohistochemical detection was
performed on frozen tissues as the available antibodies had
lower afﬁnity on ﬁxed tissues. Antibodies that are currently
available can provide sufﬁciently intense immunostaining
on parafﬁn sections, making the test more feasible [61].
Interestingly, Ki-67 is one of the ﬁve genes of proliferation
that contributes an importance weight to the Oncotype
score, out of 16 cancer-associated genes [79].
Methods
We searched PubMed to identify prospective or retro-
spective studies reporting results from analyses of Ki-67 as
either a prognostic factor or a predictive factor in women
with breast cancer. The terms used for searching were
divided into three groups to identify references on: breast
cancer and its treatment, Ki-67 and the types of studies
(Appendix 1). These were combined into a search strategy
that was limited to publications in English from 1 January
1990 to 31 July 2010. The titles and abstracts of the ref-
erences identiﬁed by this search strategy were screened by
two methodologists independently. The reference lists of
included studies were scanned to identify additional
references.
The outcomes of interest for the prognostic studies that
had to be present for inclusion of the study were OS or
DFS. In the predictive studies, the outcomes of interest
were clinical or pathological partial or complete response.
Data extracted
The items that were extracted from each publication are
listed in Appendix 2. The working group validated and
agreed on the interpretation of the data and assigned the
LOE using the recently revised deﬁnition (Table 1)[ 98].
The REMARK 20-item guideline was used to assess the
quality of the reporting in the prognostic studies identiﬁed,
only for RCTs. Items included were: the description of
patients; specimen characteristics; assay methods; study
design; statistical analysis methods; presentation of results
and study objectives and pre-speciﬁed hypotheses [71].
Results
After screening the 314 references identiﬁed by the search
strategy, 71 were included in this review (Fig. 1). The main
reason for exclusion was the type of breast cancer (ductal
carcinoma in situ). Details from the studies, including
tumour characteristics, treatment regimen, Ki-67 analysis
modalities are reported in Table 2.
Samples from randomised clinical trials
We identiﬁed 17 studies that analysed samples from
patients that had been included in RCTs in neoadjuvant and
adjuvant setting [5, 6, 11, 13, 20, 29, 32–35, 37, 39, 40, 46,
60, 66, 69, 70, 72, 77, 83, 91, 99, 108–110]. Ki-67 was
assessed as a prognostic factor for 9,185 patients in ten
studies (three with neoadjuvant treatment and seven with
adjuvant treatment), both as a prognostic and predictive
Table 1 Summary of deﬁnitions of LOE [98]
LOE Type of study Validation
I-A RCT speciﬁcally to assess the utility of the biomarker. The samples
are collected and analysed in real-time
Not necessary but could be useful
I-B RCT not speciﬁcally to assess the utility of the biomarker. The samples
are stored during the study and analysed after the study is ﬁnished,
following a protocol
One or more studies with consistent results
II-B RCT not speciﬁcally to assess the utility of the biomarker. The samples
are stored during the study and analysed after the study is ﬁnished,
following a protocol
Only one study, or several studies with inconsistent
results
II-C Non-randomized retrospective study aimed to assess the utility
of the biomarker using samples from patients in an observational setting
(standard treatment and follow-up)
Two or more studies with consistent results
III-C Non-randomized retrospective study aimed to assess the utility
of the biomarker using samples from patients in an observational setting
(standard treatment and follow-up)
Only one study, or several studies with inconsistent
results
IV–V-D No aspect of the study is prospective Not necessary because these types of studies
do not enable the clinical utility of the biomarker
to be assessed
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123factors in three studies involving 411 patients (all with
neoadjuvant treatment) and as a predictive factor in four
studies involving 520 patients (all with neoadjuvant
treatment).
In the majority of studies with Ki-67 as a prognostic
factor, both node negative (pN0) and node-positive (pN?)
patients were included. In the univariate analyses the
hazard ratio (HR) for DFS ranged from 1.06 to 2.09. Ki-67
remained an independent prognostic factor in multivariate
analyses in seven studies (HR 1.05–1.72). Despite the
differences in the methodologies used, particularly the cut-
point for Ki-67, the HR values were consistent.
Only ﬁve studies used OS as a primary objective to
evaluate Ki-67, and one analysed breast cancer-speciﬁc
survival (BCSS). In the studies with OS, Ki-67 was a sta-
tistically signiﬁcant prognostic factor (HR 1.11–1.83) in
univariate analyses; this was not reported for the trial with
BCSS as the outcome. Multivariate analyses were reported
for four trials and Ki-67 was an independent prognostic
factor in only one trial with OS; it was also signiﬁcant in
the study with BCSS.
The REMARK score for these studies ranged from 9
to 18 (on a scale from 0 to 20), with a median of 12 and
a mean of 12.8. The LOE for Ki-67 as a prognostic
factor for DFS (Table 1) was judged to be I-B since the
results were consistent across several studies, done using
material from randomized trials and with centralized
slide review.
Among the seven studies that evaluated Ki-67 as a
predictive factor, either solely or also as prognostic factor,
three studies assessed the response to neoadjuvant che-
motherapy [20, 60, 66, 70], one assessed neoadjuvant
hormonotherapy [32–35, 99], and three assessed neoadju-
vant chemotherapy and hormonotherapy [13, 46, 110].
Only one study [46] concluded that elevated Ki-67 was
predictive of response to chemotherapy; therefore, the LOE
for Ki-67 as a predictive factor was judged to be IIB.
The trials assessing the predictive value of Ki-67 in and
adjuvant setting evaluated either ﬁrst generation adjuvant
chemotherapy versus no treatment, or compared an optimal
versus sub-optimal regimen. In the IBCSG VIII/IX trial,
Viale et al. [109] did not detect any predictive value for Ki-
67 for the efﬁcacy of CMF compared with no chemother-
apy. In this analysis, the P values for Ki-67 treatment
interaction were 0.45 and 0.90 for IBCSG VIII and IX,
respectively. In two other randomized trials comparing
anthracyclines versus non anthracycline-based chemother-
apy (NEAT/BR9601), no interaction between Ki-67 and
the treatment arms was detected, suggesting that the
treatment efﬁcacy was not predicted by the Ki-67 level [6].
Finally, at least two studies assessed the predictive value of
Ki-67 for the efﬁcacy of docetaxel. Penault-Llorca et al.
[83], using material from the PACS01 trial, reported that
high Ki-67 was associated with a higher efﬁcacy of doce-
taxel. However, these results are insufﬁcient to conclude
that Ki-67 is a predictive factor.
In a study published after the literature search for this
report, Dumontet et al. [36] analysed tissue specimens for
prognostic and predictive factors in the BCIRG 001 trial.
They concluded that Ki-67 was an independent prognostic
factor in women receiving adjuvant chemotherapy for
node-positive breast cancer, but was not a predictive factor
for response to docetaxel. Overall, these studies suggest
that Ki-67 is not predictive for chemotherapy.
Samples from cohort and case–control studies
We identiﬁed 47 cohort studies that assessed the role of Ki-
67, as a prognostic factor solely (32 studies; 16,902 patient;
patients received neoadjuvant treatment in one study,
adjuvant treatment in 25 studies and no details of treatment
were available in six studies), as a predictive factor solely
(eight studies; 655 patients; patients received neoadjuvant
treatment in six, adjuvant in one, and both in one study), or
both as a prognostic and predictive factor (seven studies;
1,844 patients; all patients received neoadjuvant treatment)
[2–4, 7–9, 14–19, 21–23, 30, 42–45, 49, 54–57, 59, 62, 63,
67, 73, 76, 78, 80–82, 84, 86–90, 92, 93, 96, 97, 104, 105].
We also identiﬁed one case–control study (828 patients) in
which Ki-67 was assessed as a predictive factor for che-
motherapy [1].
About 2/3 of these studies assessing Ki-67 as a prog-
nostic factor (n = 39) reported that it was an independent
factor for DFS or OS or both. Of the 15 studies assessing
Ki-67 as a predictive factor, seven suggested that it may be
a predictive factor for response to treatment. Most studies
reported anthracycline regimen or CMF as chemotherapy
and tamoxifen or letrozole or goserelin as hormone ther-
apy. The unique case–control study considered that a high
Ki-67 value (71–100%) was independently predictive of
beneﬁt from adjuvant chemotherapy treatment [HR for
BCSS = 0.35 (95% CI = 0.18–0.69), P = 0.003].
Fig. 1 Summary from the literature search
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Although the two meta-analyses were published within a
year of each other, they did not include the same studies
(with 57 and 60% overlapping, respectively); the statistical
methods used were also different (Tables 3, 4; Fig. 2)[ 27,
100]. Neither of these meta-analyses differentiated if the
tissue samples came from randomised controlled trials or
case–control or cohort studies.
In the meta-analysis published by de Azambuja et al. in
2007 [27], the prognostic value of Ki-67 was reported only
in univariate analyses for both DFS and OS. In the analysis
for DFS, they collected data from 38 studies (including
10,954 patients) and found a HR of 1.88 (1.75–2.02) with a
ﬁxed effect model, but with signiﬁcant between-study
heterogeneity (design, type of patients and results). In the
analysis for OS concerning 35 studies (including 9,472
patients) they found a HR of 1.89 (1.74–2.06), also with a
ﬁxed effect model and signiﬁcant between-study hetero-
geneity. In sub-analyses, similar results were observed, but
no heterogeneity was found for pN? patients or for
untreated patients (pN0 for DFS and pN0/pN? for OS).
In the meta-analysis of Stuart-Harris et al. in 2008 [100],
after adjustment for probable publication bias, a high level
of Ki-67 was associated with poor DFS and OS and this
remained statistically signiﬁcant in multivariate analyses.
The pooled adjusted HRs were 2.05 (1.80–2.33) and 1.88
(1.55–2.27) for DFS and OS in univariate analyses, and
1.76 (1.56–1.98) and 1.42 (1.14–1.77) in multivariate
analyses, respectively. In the analyses for DFS, there were
no evidence of signiﬁcant between-study heterogeneity, but
this was not the case for OS.
The authors in both these meta-analyses acknowledged
that the included studies used different eligibility criteria,
study design, methods for measuring Ki-67 and cut-point
values. Despite the differences, the results are consistent,
and thus reinforce the value of Ki-67 as a prognostic factor.
Narrative reviews
Four narrative reviews were identiﬁed [24, 107, 111, 115].
None of these reviews assessed the predictive value of Ki-
67. Two of them, Weigel and Dowsett [111] and Yer-
ushalmi et al. [115] summarized the results from the meta-
analyses described above. Colozza et al. [24] who looked at
several markers included 15 studies (5,137 patients) for Ki-
67. They concluded that Ki-67 was a statistically signiﬁ-
cant prognostic factor but not a standard one at present, due
to the lack of standardization for pre-analytical steps,
staining procedures and scoring methods. Urruticoechea
et al. [107] reviewed 40 trials, involving more than 11,000
patients). They found strong evidence that Ki-67 was a
prognostic factor for pN0 patients in univariate analyses,
and that it remained signiﬁcant in multivariate analyses. In
the studies with pN? patients or mixed pN0/pN? patients,
the results were less clear, although one study concluded
that Ki-67 was a candidate biomarker for predicting
docetaxel efﬁcacy in ER?,p N ? breast cancer [83].
Discussion
Early detection and improvements in systemic neoadjuvant
and adjuvant therapies explain the observed decrease in
mortality in breast cancer [53]. However, since chemo-
therapy is associated with adverse effects, it is important to
be able to tailor treatment strategies for each patient.
Companion diagnostic tests, such as HER2 or ER mea-
surements, which are by essence predictive, are already key
actors in daily therapeutic strategies. In parallel, non-
associated tests, such as proliferation biomarkers, continue
to be investigated in the hope of ﬁnding reliable tools to
help to identify those women who are most likely to beneﬁt
from chemotherapy.
Ki-67 was signiﬁcantly associated with DFS in multi-
variate analyses in seven RCTs and two meta-analyses with
consistent HRs or relative risks (RRs) [27, 29, 32–35, 39,
40, 83, 99, 100, 108, 109]. Although, more heterogeneous,
similar results were reported in studies using samples from
cohort studies. The HRs and RRs reported for Ki-67 in
most of these studies were within the same ranges as those
found for other validated prognostic markers (ER, HER2,
uPA, node status, histological grade) (Table 5)[ 10, 64, 94,
100, 113].
The evidence reviewed here, with consistent results
between the studies allowing the attribution of an LOE I-B,
validates the use of Ki-67 as a prognostic factor for DFS in
patients receiving adjuvant therapy. As none of the studies
were speciﬁcally designed to assess Ki-67 as a prognostic
factor, the LOE cannot be I-A. A LOE I deﬁnes a marker
that is ready for clinical use, therefore, justifying its status
as a biomarker as suggested by Diamandis [31]. This level
is based on the hierarchical classiﬁcation for medical utility
of a biomarker proposed by Simon et al. in 2009 [98], an
updated revision of the initial classiﬁcation proposed by
Hayes et al. in 1996 [52]. This differs dramatically from the
LOE proposed by Colozza et al. [24] who suggested a level
III or even IV. However, it should be emphasised that our
conclusion is based on results from studies using samples
from RCTs with central review of the marker; that was not
the case in the review conducted by Colozza et al. that
included studies published before 2004. This implies that
standardization of the techniques and counting methods
ensuring efﬁcient and practical alternatives to centralized
testing (i.e. automated staining and image analysis) will be
necessary for everyday practice.
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123The results from the studies using samples from patients
included in RCTs do not provide sufﬁcient proof to con-
clude that Ki-67 is a predictive factor for short-term or
long-term response to chemotherapy, since the study
designs were not suitable for answering this question. The
LOE is therefore II-B and a higher LOE will only be
possible if suitably designed prospective studies are con-
ducted. Nevertheless, an association between high Ki-67
expression at baseline and immediate response to hormo-
notherapy or chemotherapy in the neoadjuvant setting was
reported in seven case series [14, 15, 73, 78, 82, 84, 90],
two of them with pathological complete response (pCR)
[73, 78]. The studies in the neoadjuvant chemotherapy
setting analysed pCR as the endpoint. In contrast, the
studies in the neoadjuvant hormonotherapy setting, used a
clinical response endpoint. In breast cancer samples from
women with incomplete pathological response after neo-
adjuvant therapy, the Ki-67 expression in the residual
tumour was reported to be prognostic, irrespective of the
original pre-treatment value [40, 59, 102].
Prognostic variables are needed in clinical practice.
Histological grade can clearly distinguish between low and
high risks tumours (grade 1 vs. grade 3) in terms of out-
comes. However, about 40–50% of breast cancers are
classiﬁed as grade 2 with a less well-deﬁned risk. The
histological grading system is constructed from a parame-
ter of differentiation (glandular formation), nuclear
appearance and a clear proliferation parameter (mitotic
count). This explains why grade and Ki-67 index are clo-
sely linked, and why the grade is not always integrated in
the multivariated models used for assessing Ki-67. The fact
that such a link exists does not mean that the parameters
are redundant and the use of Ki-67 index in a grade 2
population could be particularly useful to sub-classify them
[2]. Patients with ER? tumours are systematically treated
by hormonotherapy today in the absence of contra-indica-
tions. It is possible that a Ki-67 assessment prior to
deciding to propose additional adjuvant chemotherapy
might be useful for a subset of ER? patients with grade 2
tumours.
The choice of the cut-point has a major impact in
practice, as it determines which patients are classiﬁed as
‘high Ki-67’, and therefore which have a poorer prognosis.
These patients will generally receive more aggressive
therapy. In the published studies reviewed, many different
Fig. 2 Repartition of the studies included in the meta-analyses
published by de Azambuja et al. [27] and Stuart-Harris et al. [100].
The numbers of studies common to both meta-analyses are shown in
the overlapping circles and those unique to either one of the meta-
analyses are shown in the non-overlapping parts of the circles. DFS
Disease-free survival; OS overall survival
Table 3 Comparison of the methods used in the meta-analyses published by de Azambuja et al. [27] and Stuart-Harris et al. [100]
de Azambuja et al. [27] Stuart-Harris et al. [100]
Publication year 2007 2008
Period for literature
search
Up to May 2006 January 1995–September 2004
Exclusion criteria Non-English publications Non-English publications
Studies with fewer than 100 patients
Number of studies
identiﬁed
a
46 43
Included in DFS
analysis
38 20
Included in OS
analysis
35 19
Inclusion of studies
for meta-analyses
Studies that provided an HR or data that
enabled the HR to calculated
Only studies that provided an HR for either OS or DFS, in either univariate
or multivariate analysis; if no 95% CI it was calculated
a See Fig. 2 for details of common and unique studies
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123ways to select a cut-point were used, deﬁning two or three
subgroups. These include an arbitrary choice based either
on the different cut-points proposed in the literature or the
use of the ‘‘signiﬁcant’’ mean value from an ‘in house’
series. In our review of studies using samples from RTCs,
most arbitrary cut-points for adjuvant treatment choice
were distributed between 5 and 34% with 10 or 20% being
the most frequently used values (Table 2).
Table 4 Description of meta-analyses of studies of Ki-67 as a prognostic factor
Reference Factors studied Outcome Results
Analysis: number
of studies (number of patients)
Search strategy described
(yes/no)
Date range number of studies
identiﬁed (number of
patients)
de Azambuja
et al. [27]
Ki-67
Yes
Up to May 2006
Identiﬁed: 68 studies (?
patients)
DFS
All studies: 38 studies (10,954 patients) Fixed effect HR: 1.88 (1.75–2.02)
P-heterogeneity = 0.01
Random effect HR: 1.93 (1.74–2.14)
Node negative: 15 studies (3,370 patients) Fixed effect HR: 2.20 (1.88–2.58)
P-heterogeneity = 0.03
Random effect HR: 2.31 (1.83–2.92)
Node positive: 8 studies (1,430 patients) Fixed effect HR: 1.59 (1.35–1.87)
P-heterogeneity = 0.68
Node negative (untreated): 6 studies (736 patients) Fixed effect HR: 2.72 (1.97–3.75)
P-heterogeneity = 0.89
OS
All studies: 35 studies (9,472 patients) Fixed effect HR: 1.89 (1.74–2.06)
P-heterogeneity\0.001
Random effect HR: 1.95 (1.70–2.24)
Node negative: 9 studies (1,996 patients) Fixed effect HR: 2.19 (1.76–2.72)
P-heterogeneity = 0.001
Random effect HR: 2.54 (1.65–3.19)
Node positive: 4 studies (857 patients) Fixed effect HR: 2.33 (1.83–2.95)
P-heterogeneity = 0.44
Node negative/positive (untreated): 2 studies (238
patients)
Fixed effect HR: 1.79 (1.22–2.63)
P-heterogeneity = 0.36
Stuart-Harris
et al. [100]
Ki-67, mitotic index, PCNA,
LI
Yes
January 1995–September
2004
Identiﬁed: 43 studies (15,790
patients)
DFS
Univariate analysis: 15 studies (?) Unadjusted HR: 2.18 (1.92–2.47) P\10
-5
P-heterogeneity = 0.21
P-publication bias = 0.002
Adjusted HR (4 studies added): 2.05 (1.80–2.33)
Multivariate analysis: 14 studies (?) Unadjusted HR: 1.84 (1.62–2.10) P\10
-5
P-heterogeneity = 0.93
P-publication bias = 0.019
Adjusted HR (5 studies added): 1.76 (1.56–1.98)
OS
Univariate analysis: 12 studies (?) Unadjusted HR: 2.09 (1.74–2.52) P\10
-5
P-heterogeneity = 0.037
P-publication bias = 0.074
Adjusted HR (4 studies added): 1.88 (1.55–2.27)
Multivariate analysis: 13 studies (?) Unadjusted HR: 1.73 (1.37–2.17) P\10
-5
P-heterogeneity\10
-5
P-publication bias = 0.001
Adjusted HR (5 studies added): 1.42 (1.14–1.77)
PCNA Proliferating cell nuclear antigen; LI labelling index
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123The use of data-derived ‘optimal’ cut-points can result
in serious bias due to different patient populations in each
series. It should be stressed that transforming continuous
variables, such as the Ki-67 index, into two categories can
lead to a loss of power of the biomarker [88, 95, 108, 109].
In addition, this is unrealistic at the individual level, since
it suggests that patients, who have tumours with Ki-67
levels close to the cut-point but on either side of the cut-
point, are very different, whereas in reality they are prob-
ably very similar. Technically it is not necessary for sta-
tistical analysis to have a binary variable, and it has been
show that a model with continuous values provides more
information [95]. In clinical practice, one way of express-
ing the results is to use two cut-point values which deﬁne a
central ‘grey’ area between the low and high values. For
patients whose Ki-67 level falls in this grey area, other
factors could be considered in the decision to offer che-
motherapy or not. This is the approach adopted by the St
Gallen International Expert Consensus who recommended
the use of Ki-67 to measure proliferation [47, 48, 95];
women with ER? tumours and ‘high’ Ki-67 (i.e. [30%)
should receive chemo-hormonotherapy, those with ‘low’
Ki-67 (B15%) (luminal A tumours) should receive hor-
monotherapy alone and the ‘intermediate’ level (16–30%)
is not decisive for therapeutic decision.
Ki-67 expression is detected by immunohistochemical
techniques on histological slides. Molecular testing using
RT-QPCR on ﬁxed-parafﬁn embedded tissue samples is
also feasible [28] but not used in practice. Both techniques
give quantitative results but the qualitative aspect of
tumour heterogeneity is only accessible on histology slides.
Comparative studies are in progress but the results are not
yet available. Moreover, both techniques, as for all bio-
markers, need standardized pre-analytical conditions which
require cooperation between radiologists, surgeons, and
pathologists. Most laboratories use MIB-I or SP6 anti-
bodies for immunohistochemistry that provide highly
comparable results, although SP6 appears to be better
suited for image analysis [116]. However, the methods of
antigen retrieval from parafﬁn-embedded samples, the
concentrations of antibodies, the time of incubation, as well
as the ampliﬁcation reagents vary and may signiﬁcantly
inﬂuence the ﬁnal results [114, 116]. We observed this
variation in the studies analysed in this review (Table 2).
Automatic immunostaining was reported to be used in only
three of the published studies, despite the fact that most
laboratories are nowadays equipped with such systems [88,
108, 109]. Also, the way samples are treated immediately
after collection and the way they are stored may affect the
ﬁnal results, but generally only sparse information on this
was provided in most of studies reported. In general, all
studies reported using a negative control. However, there
was no standardized positive control for staining calibra-
tion. Some studies used tonsil tissue, while others used
known highly positive breast cancer tissue. The intensity of
nuclear staining that was considered to be positive also
varied; in some cases any staining was taken as positive,
whereas in others positivity required ‘marked’ staining.
Some studies reported using ‘hot spots’ (or areas of intense
staining) for the assessment, whereas others used ﬁelds
with different intensity of staining giving the result as a
mean value. Signiﬁcant variation in the number of ﬁelds
examined, the number of tumour cells counted or esti-
mated, the use of a graticule for counting or the use of
automated counting systems was also seen. Some studies
reported a double reading of all slides, or of a certain
percentage of slides.
Due to limits in histological quantitative analysis and
tumour heterogeneity, leading to inter/intra-observer vari-
ations on grade scoring, some grade 2 tumours are mis-
classiﬁed as grade 1, and also some grade 1 tumours are
mis-classiﬁed as grade 2. The assessment of Ki-67 levels in
these borderline cases provides additional information to
clinicians. Similar overlap exists between grade 2 and
grade 3 tumours, but without a signiﬁcant impact on
therapeutic decision. In view of the inaccuracies expected
in the Ki-67 index values, partly due to the heterogeneity of
the techniques as discussed above, and partly due to tumour
heterogeneity, it may be useful to generalize automated
quantitative image analysis, to report both ‘hot spots’ and
mean Ki-67 values, and to expand the 16–30% interme-
diate level of St Gallen to 11–30% [47]. This wider
intermediate level would ensure a better identiﬁcation of
tumours with low and high levels of Ki-67. The risk of
making an error when assessing a Ki-67 score \10 or
[30% will be low in routine practice, but is to be expected
for the intermediate level between 11 and 30%, requiring,
therefore, double assessment or automated image analysis.
Reporting key details are essential to assess the reli-
ability of the study results. Initiatives such as the CON-
SORT guidelines have been shown to improve the quality
of reporting for RCTs [74, 75]. In a similar way, the
REMARK guidelines were developed to improve reporting
Table 5 Summary of assessment of various markers as prognostic
factors for DFS in women with breast cancer
Reference
a Marker HR (95% CI)
Stuart-Harris et al. [100] Ki-67 1.76 (1.56–1.98)
Rakha et al. [94] SBR grade (3 vs. 1) 1.6 (1.3–2.0)
Look et al. [64] uPA/PAI-1 (pN0) 2.37 (1.78–3.16)
Rakha et al. [94] Node status 1.5 (1.4–1.7)
Wirapati et al. [113] ER (neg. vs. high) 2.2 (1.6–3.0)
Blows et al. [10] HER2 1.55 (1.23–1.96)
SBR Scarf–Bloom–Richardson histological grading system
a Not all patients received systemic adjuvant treatment
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123of prognostic studies and their results [71]. Mallett et al.
[68] reported in 2010 the results from an analysis of reports
of prognostic tumour marker studies published in 2006 and
2007 using the REMARK score. The aim of their study was
to assess if the publication of the guidelines had had an
immediate impact on the quality of the reported studies.
Although most of the studies reported the number of
patients in the analyses (98%), only just over half reported
the number of eligible patients (56%) and excluded patients
(54%). Only 36% of the reports clearly deﬁned the out-
comes analysed. The authors concluded that although good
reporting is essential for the interpretation and clinical
application of prognostic studies, the standards of reporting
in 2006 and 2007 were poor. They called for a wider use of
the REMARK guidelines to help improve reporting and
enhance prognostic research. The results of our review
show that articles published prior to the publication of
REMARK in 2005 had a lower range of REMARK scores
(n = 9; 6–13) than those published after (n = 9; 10–18)
which suggests that the quality of reporting has improved.
Conclusions
TheresultsfromthisreviewshowthatKi-67 providesuseful
information for therapeutic decisions in breast cancer
patients. It is an independent prognostic factor for DFS and
the greatest beneﬁts from Ki-67 assessment could be
observed in patients with ER? breast cancers. It is not pre-
dictive for chemotherapy, but high KI-67 was found to be
associated with immediate pCR in the neoadjuvant setting.
In view of these results, international guidelines should
help to standardize the pre-analytical phase, the staining
techniques and the counting methods. We also need to
standardize the cut-point determination to ensure that Ki-
67 results can be used with conﬁdence in clinical practice.
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